Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
Gut and Liver · 15.09.2023 · 17 (5) · 777-785
DOI: 10.5009/gnl220278 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 29.12.2022. Verfasst von Jae Hee Cheon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Behcet Syndrome, Intestinal Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Korea Ltd.
Abstract (Originalsprache)
Background/Aims: To date, there is no prospective study that specifically investigated the efficacy of infliximab in intestinal Behçet's disease (BD). This study evaluated the efficacy of infliximab in patients with moderate-to-severe active intestinal BD that are refractory to conventional therapies.
Methods
This phase 3, interventional, open-label, single-arm study evaluated clinical outcomes of infliximab treatment in patients with moderate-to-severe intestinal BD. The coprimary endpoints were clinical response, decrease in disease activity index for intestinal BD (DAIBD) score ≥20 from weeks 0 to 8 for the induction therapy and week 32 for the maintenance therapy.
Results
A total of 33 patients entered the induction therapy and were treated with infliximab 5 mg/kg intravenously at weeks 0, 2, and 6. The mean DAIBD score changed from 90.8±40.1 at week 0 to 40.3±36.4 at week 8, with a significant mean change of 50.5±36.4 (95% confidence interval, 37.5 to 63.4; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
- Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
- Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
ORCID-Profile: Jae Hee Cheon, Hyun-Soo Kim, Dong Soo Han, Sung Kook Kim, Sung Jae Shin, Joo Sung Kim, Byong Duk Ye, Geun Am Song, YoungJa Lee, Youngdoe Kim, Yoosun Lee, Won Ho Kim
Förderung
- Janssen Korea Ltd
Zitieren
APA
Cheon, J. H., Kim, H. S., Han, D. S., Kim, S. K., Shin, S. J., Kim, J. S., Ye, B. D., Song, G. A., Lee, Y., Kim, Y., Lee, Y., Kim, W. H., & BEGIN Study Group (2023). Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN). Gut and Liver, 17(5), 777-785. https://doi.org/10.5009/gnl220278
Vancouver
Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, et al. Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN). Gut and Liver. 2023;17(5):777-785. doi:10.5009/gnl220278
BibTeX
@article{Cheon2023,
author = {Cheon, Jae Hee and Kim, Hyun-Soo and Han, Dong Soo and Kim, Sung Kook and Shin, Sung Jae and Kim, Joo Sung and Ye, Byong Duk and Song, Geun Am and Lee, YoungJa and Kim, Youngdoe and Lee, Yoosun and Kim, Won Ho and BEGIN Study Group, BEGIN Study Group},
title = {Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)},
journal = {Gut and Liver},
year = {2023},
volume = {17},
number = {5},
pages = {777--785},
doi = {10.5009/gnl220278}
}
EUVIMED